Navacaprant (NMRA-140)
Major Depressive Disorder (MDD)
Key Facts
About Neumora Therapeutics
Neumora Therapeutics aims to transform the treatment of neuropsychiatric and neurodegenerative disorders by developing precision therapies based on biological subtypes. The company's platform integrates data science, neurobiology, and clinical development to match the right drug to the right patient. Its most advanced asset, navacaprant, represents a novel mechanism for depression, with a Phase 3 program underway. Backed by significant venture capital and a high-profile IPO, Neumora is positioned as a leader in the next generation of neuroscience drug development.
View full company profileAbout Neumora Therapeutics
Neumora Therapeutics aims to transform the treatment of neuropsychiatric and neurodegenerative disorders by developing precision therapies based on biological subtypes. The company's platform integrates data science, neurobiology, and clinical development to match the right drug to the right patient. Its most advanced asset, navacaprant, represents a novel mechanism for depression, with a Phase 3 program underway. Backed by significant venture capital and a high-profile IPO, Neumora is positioned as a leader in the next generation of neuroscience drug development.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| XEN1101 | Xenon Pharmaceuticals | Phase 3 |
| BHV-5000 (NMDA antagonist) | Biohaven | Phase 1 |
| Undisclosed CNS Candidate | Alto Neuroscience | Phase 1 |
| MW-101 | MindWalk Holdings | Phase 2 |
| NPH-101 | Neuphoria Therapeutics | Phase 2 |
| Itruvone (PH10) | Vistagen Therapeutics | Phase 2 |